Leaflet: information for the user

Rivastigmina Teva 4.6 mg/24 h transdermal patches EFG

Rivastigmina Teva 9.5 mg/24 h transdermal patches EFG

Rivastigmina Teva 13.3 mg/24 h transdermal patches EFG

Read this leaflet carefully before you start using this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, consult your doctor, pharmacist or nurse.
• This medicine has been prescribed for you only, and you must not give it to others even if they have the same symptoms as you, as it may harm them.
• If you experience any side effects, consult your doctor, pharmacist or nurse, even if they are not listed in this leaflet. See section 4.

1. What is Rivastigmina Teva and what is it used for

2. What you need to know before you start using Rivastigmina Teva

3. How to use Rivastigmina Teva

4. Possible side effects

5. Storage of Rivastigmina Teva

6. Contents of the pack and additional information

The active ingredient ofRivastigmina Tevais rivastigmina.

Rivastigmina belongs to a class of medications called cholinesterase inhibitors. In patients with Alzheimer's disease, certain nerve cells die in the brain, resulting in low levels of acetylcholine neurotransmitters (a substance that allows nerve cells to communicate with each other).Rivastigmina acts by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes,rivastigminapermits an increase in acetylcholine in the brain, helping to reduce the symptoms of Alzheimer's disease.

Rivastigmina is used for the treatment of adult patients with mild to moderately severe Alzheimer's disease, a progressive brain disorder that gradually affects memory, intellectual capacity, and behavior.

Do not use Rivastigmina Teva

• if you are allergic to rivastigmina (the active ingredient of Rivastigmina Teva) or to any of the other components of this medication (listed in section 6),

• if you have ever had an allergic reaction to a similar medication (carbamate derivatives),

• if you have a skin reaction that extends beyond the size of the patch, if there is a more intense local reaction (such as blisters, increased skin inflammation, swelling) and if there is no improvement within 48 hours after removing the transdermal patch.

If you are in any of these situations, inform your doctor and do not use Rivastigmina Teva transdermal patches.

Warnings and precautions

Consult your doctor before starting to use Rivastigmina Teva

• if you have or have had any heart disease such as irregular or slow heart rhythm, prolonged QTc, family history of prolonged QTc, torsades de pointes or low levels of potassium or magnesium in the blood,
• if you have or have had any active stomach ulcer,
• if you have or have had any difficulty urinating,
• if you have or have had any seizures,
• if you have or have had any severe respiratory disease,
• if you suffer from tremors,
• if you have a low body weight,
• if you have gastrointestinal reactions such as dizziness (nausea), dizziness (vomiting) and diarrhea. You may become dehydrated (loss of a large amount of fluid) if the vomiting or diarrhea is prolonged,

(if you have liver problems (hepatic insufficiency)).

If you are in any of these situations, your doctor may consider the need for closer monitoring while you are being treated.

If you have not used the patches for more than three days, do not put another one on without consulting your doctor first.

Use in children and adolescents

Rivastigmina Teva should not be used in the pediatric population for the treatment of Alzheimer's disease.

Use of Rivastigmina Teva with other medications

Inform your doctor or pharmacist if you are using, have used recently or may need to use any other medication.

Rivastigmina Teva may interfere with anticholinergic medications some of which are medications used to relieve stomach cramps or spasms (for example; diciclomina), for the treatment of Parkinson's disease (for example; amantadina) or to prevent travel sickness (for example; difenhidramina, escopolamina or meclizina).

Rivastigmina Teva should not be administered at the same time as metoclopramide (a medication used to relieve or prevent nausea and vomiting). Taking the two medications together may cause problems such as stiffness in the limbs and hand tremors.

If you need to undergo surgery while using Rivastigmina Teva transdermal patches, inform your doctor that you are using them, as they may excessively potentiate the effects of some muscle relaxants during anesthesia.

Caution should be exercised when using Rivastigmina Teva with beta blockers (medications such as atenolol used to treat hypertension, angina and other heart conditions). Taking the two medications together may cause complications such as a decrease in heart rate (bradycardia) that may lead to fainting or loss of consciousness.

Caution should be exercised when rivastigmina is taken with other medications that may affect your heart rhythm or the electrical system of your heart (prolongation QT).

Pregnancy, breastfeeding and fertility

If you are pregnant or breastfeeding, think you may be pregnant or are planning to become pregnant, consult your doctor or pharmacist before using this medication.

If you are pregnant, it is necessary to evaluate the benefits of using Rivastigmina Teva against the possible adverse effects on the fetus. Rivastigmina Teva should not be used during pregnancy unless it is clearly necessary.

You should not breastfeed during your treatment with Rivastigmina Teva transdermal patches.

Driving and operating machinery

Your doctor will inform you if your condition allows you to drive or use machinery safely. Rivastigmina Teva transdermal patches may cause dizziness and severe confusion. If you feel dizzy or confused, do not drive, use machinery or perform other tasks that require your attention.

Follow exactly the administration instructions of this medication indicated by your doctor. In case of doubt, consult your doctor, pharmacist or nurse.

IMPORTANT:

• Remove the previous patch before putting on a new one.
• Only one patch per day.
• Do not cut the patch into pieces.
• Press the patch firmly against the skin with the palm of your hand for at least 30 seconds.

How to start treatment

Your doctor will indicate the most suitable dose of rivastigmine transdermal patches for your case.

Normally, treatment starts with rivastigmine 4.6 mg/24 h.

• The recommended daily dose is rivastigmine 9.5 mg/24 h. If this dose is well tolerated, your doctor may consider increasing the dose to 13.3 mg/24 h.
• Only wear one rivastigmine patch at a time and replace the patch with a new one every 24 hours.

Your doctor may adjust the dose during treatment depending on your individual needs.

If you have not used the patches for more than three days, do not put on a new one without consulting your doctor. Treatment with transdermal patches can be restarted at the same dose if treatment is not interrupted for more than three days. Otherwise, your doctor will have you restart your treatment with rivastigmine 4.6 mg/24 h.

Rivastigmine can be used with food, drink and alcohol.

Where to place rivastigmine transdermal patches

Make sure the skin is clean, dry and free of hair, powders, oil, moisturizer or lotion that may prevent the patch from sticking well to the skin, without cuts, redness or irritation.

Remove the patch carefully before putting on a new one. Wearing multiple patches on your body may expose you to an excessive amount of this medication, which could be potentially hazardous.

Put on one patch per day in one of the possible areas, as shown in the following diagrams:

• Upper left or upper right arm
• Upper left or upper right chest (avoiding the breasts)
• Upper left or upper right back
• Lower left or lower right back

Every 24 hours, remove the previous patch before putting on a new one in only one of the possible areas.

Front

Ó Ó Ó Ó

Back

Ó Ó Ó

Each time you change the patch, remove the previous day's patch before putting on a new one in a different area of the skin (for example, one day on the right side of the body and the next day on the left side; or one day on the upper body and the next day on the lower body). Wait at least 14 days to put a new patch in the same area of the skin.

How to apply rivastigmine transdermal patches

Rivastigmine patches are thin, transparent plastic and stick to the skin. Each patch is in a sealed pouch that protects it until it is put on. Do not open the pouch or remove the patch until you are ready to put it on.

You must wear the patch continuously until you change it for a new one.

When putting on a new patch, you can try different areas to find the ones that are most comfortable and where your clothes do not rub against the patch.

How to remove Rivastigmina Teva transdermal patches

Remove the patch slowly from one edge, being careful not to pull on the skin. If there are any remaining adhesive residues on the skin, soak the area with warm water and mild soap or use baby oil to remove it. Do not use alcohol or other solvents (nail polish removers or other solvents).

After removing the patch, wash your hands with soap and water. If you come into contact with your eyes or if your eyes become red after handling the patch, wash immediately with plenty of water and consult a doctor if the symptoms do not resolve.

Can you wear Rivastigmina Teva patches when bathing, swimming or exposing yourself to the sun?

• Bathing, swimming or showering should not affect the patch. Make sure it does not come off partially while doing these activities.
• Do not expose the patch to an external heat source (e.g. excessive sunlight, sauna, solarium) for long periods of time.

What to do if a patch falls off

If a patch falls off, put on a new one for the rest of the day and change it the next day at the usual time.

When and for how long should you wear Rivastigmina Teva transdermal patches

• To benefit from your treatment, you must put on a new patch every day, preferably at the same time.
• Only wear one rivastigmine patch at a time and replace the patch with a new one every 24 hours.

If you use more Rivastigmina Teva than you should

If you accidentally put on more than one patch, remove all the patches from the skin and inform your doctor, pharmacist or call the Toxicological Information Service, phone 91 562 04 20 (indicating the medication and the amount administered). You may need medical attention. Some people who have taken accidentally high doses of rivastigmine orally have had a feeling of discomfort (nausea), vomiting, diarrhea, high blood pressure and hallucinations. They may also produce a slowing of heart rate and fainting.

If you forget to use Rivastigmina Teva

If you realize you have forgotten to put on a patch, put it on immediately. The next day, put on the next patch at the usual time. Do not put on two patches to compensate for the one you forgot.

If you interrupt treatment with rivastigmina

Inform your doctor or pharmacist if you stop using the patches.

If you have any other doubts about the use of this product, ask your doctor or pharmacist.

Like all medications, Teva Rivastigmina transdermal patches may cause side effects,

although not everyone will experience them.

You may experience side effects more frequently when you first start treatment or when your dose is increased.

Generally, side effects will slowly disappear as your body gets used to the medication.

If you notice any of the following serious side effects, remove the patch and immediately inform your doctor.

Common (may affect up to 1 in 10 people)

• Loss of appetite
• Decreased appetite
• Sensation of dizziness
• Sensation of numbness
• Sensation of agitation
• Urinary tract infection (infection in the parts of the body that store or release urine)
• Urinary incontinence (inability to stop urinating properly)
• Stomach problems such as nausea or vomiting, diarrhea, indigestion, and stomach pain
• Anxiety
• Depression
• Headache
• Fainting
• Sensation of fatigue or weakness
• Fever
• Weight loss
• Confusion
• Delirium
• Rash
• Reaction on the skin where the patch was used, such as redness, rash, swelling, inflammation, or skin irritation.

Uncommon (may affect up to 1 in 100 people)

• Problems with your heart rhythm, such as slow heart rate
• Stomach ulcer
• Dehydration (excessive fluid loss)
• Hypervigilance (high level of activity, restlessness)
• Aggression

Rare (may affect up to 1 in 1,000 people)

• Falls

Very rare (may affect up to 1 in 10,000 people)

• Tremors, muscle spasms, or movement disorders resulting from effects on a part of the brain that regulates movement

Unknown (frequency cannot be estimated from available data)

• Itching, redness, blisters, inflammation of allergic skin.
• Worsening of Parkinson's disease symptoms, such as tremor, rigidity, and difficulty moving

• Pancreatitis, symptoms include upper abdominal pain,
• often accompanied by nausea or vomiting.
• Abnormal heart rhythm or irregular heartbeat
• Hallucinations (seeing, hearing, or feeling things that do not exist)
• High blood pressure
• Seizures (attacks)
• Tremors
• Drowsiness
• Liver inflammation (yellowing of the skin, yellowing of the white of the eyes, abnormal darkening of urine, or unexplained nausea, vomiting, fatigue, and loss of appetite)
• Changes in liver function tests
• Sensation of restlessness
• Nightmares
• Syndrome of Pisa (a disease that involves involuntary muscle contraction with abnormal flexion of the body and head to one side)

If you notice any of the side effects listed above, remove the patch and immediately inform your doctor.

Other side effects experienced with rivastigmina capsules or oral solution and that may occur with patches:

Common (may affect up to 1 in 10 people)

• General feeling of discomfort
• Feeling of confusion
• Increased sweating

Uncommon (may affect up to 1 in 100 people)

• Difficulty sleeping

Rare (may affect up to 1 in 1,000 people)

• Ulcer in the intestine
• Back, jaw, and chest pain, caused by physical exertion and problems with blood flow to the heart

Very rare (may affect up to 1 in 10,000 people)

• Gastrointestinal bleeding; manifested as blood in the stool or vomiting blood
• Some people who have been severely nauseated (vomiting) have had a tear in part of the tube that connects their mouth to their stomach (esophagus)

Reporting of side effects

If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this prospectus. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information about the safety of this medication.

Keepthis medicationout of the sight and reach of children.

Do not usethis medicationafter the expiration date that appears onthe box and the packageafter CAD. The expiration date is the last day of the month indicated.

This medication does not require special temperature conditions.

Keep the transdermal patch inside the package until use.

Do not use any patch if you observe that it is damaged or shows signs of manipulation.

Keep in the original packaging to protect it from light.

After removing a patch, fold it in half with the adhesive side inwards and press. After placing it in the original package, ensure that it is out of the reach of children. After removing the patch, do not touch your eyes, and wash your hands thoroughly with water and soap. If your household waste is disposed of by incineration, you can throw the patch in your household waste. If not, take the used patches to the pharmacy, preferably in the original packaging.

Medications should not be thrown down the drain or in the trash. Deposit the containers and medications you no longer need at the SIGREpoint of the pharmacy. In case of doubtask your pharmacist how to dispose of the containers and medications you no longer need. In this way, you will help protect the environment.

Composition of Rivastigmina Teva

The active ingredient is rivastigmina.

Rivastigmina Teva 4,6 mg/24 h transdermal patches EFG

Each patch releases 4.6 mg of rivastigmina in 24 hours, measures 5 cm2and contains 9 mg of rivastigmina.

Rivastigmina Teva 9,5 mg/24 h transdermal patches EFG

Each patch releases 9.5 mg of rivastigmina in 24 hours, measures 10 cm2and contains 18 mg of rivastigmina.

Rivastigmina Teva 13,3 mg/24 h transdermal patches EFG

Each patch releases 13.3 mg of rivastigmina in 24 hours, measures 15 cm2and contains 27 mg of rivastigmina.

The other components are:

Backing: Polyester backing

Fluor-coated polyester backing

Medicine reservoir: Acrylic adhesive, copolymer of polyacrylate (butylmethacrylate-cometilmethacrylate)

Adhesive matrix: Silicone adhesive

Printing ink: Black printing ink

Appearance of the product and contents of the package

Each transdermal patch is a thin patch composed of three layers. The outer layer is translucent, white and marked in black with the following:

Rivastigmina Teva 4,6 mg/24 h transdermal patches EFG

“Rivastigmina 4,6 mg/24 h”

Rivastigmina Teva 9,5 mg/24 h transdermal patches EFG

“Rivastigmina 9,5 mg/24 h”

Rivastigmina Teva 13,3 mg/24 h transdermal patches EFG

“Rivastigmina 13,3 mg/24 h”

Each patch is packaged in individual child-resistant blisters, sealed.

Rivastigmina Teva 4,6 mg/24 h transdermal patches EFG

The patches are available in packages containing 7, 10, 30, 60 and 90 blisters and in multi-packages containing 60 (2 x 30) or 90 (3 x 30) blisters.

Rivastigmina Teva 9,5 mg/24 h transdermal patches EFG

The patches are available in packages containing 7, 10, 30, 60 and 90 blisters and in multi-packages containing 60 (2 x 30) and 90 (3 x 30) blisters.

Rivastigmina Teva 13,3 mg/24 h transdermal patches EFG

The patches are available in packages containing 7, 30, 60 and 90 blisters and in multi-packages containing 60 (2 x 30) and 90 (3 x 30) blisters.

Only some package sizes may be marketed.

Marketing authorization holder and responsible manufacturer

Marketing authorization holder

Teva Pharma S.L.U.

C/ Anabel Segura, nº 11 Edificio Albatros B, 1ª planta

28108 Alcobendas – Madrid

Spain

Responsible manufacturer

Eurofins Phast GmbH

Kardinal-Wendel-Strasse 16

66424 Homburg

Germany

Delph-i GmbH

Schöntalweg 7+9

63849 Leidersbach,

Germany

Merckle GmbH

Ludwig-Merckle-Strasse, 3 Blaubeuren D-89143

Germany

Teva Operations Poland SP.Z.O.O.

Ul. Mogilska 80

31-546 Krakow, Poland

This medicinal product is authorized in the Member States of the European Economic Area

with the following names

AustriaRivastigmin ratiopharm 4,6 mg/24 Stunden transdermales Pflaster

Rivastigmin ratiopharm 9,5 mg/24 Stunden transdermales Pflaster

Rivastigmin ratiopharm 13,3 mg/24 Stunden transdermales Pflaster

GermanyRivastigmin-ratiopharm 4,6 mg/24 Stunden transdermales Pflaster

Rivastigmin-ratiopharm 9,5 mg/24 Stunden transdermales Pflaster

Rivastigmin-ratiopharm 13,3 mg/24 Stunden transdermales Pflaster

SpainRivastigmina Teva 4,6 mg/24 h Transdermal Patch EFG

Rivastigmina Teva 9,5 mg/24 h Transdermal Patch EFG

Rivastigmina Teva 13,3 mg/24 h Transdermal Patch EFG

NetherlandsRivastigmine Teva 4,6 mg/24 u, patch for transdermal use

Rivastigmine Teva 9,5 mg/24 u, patch for transdermal use

Rivastigmine Teva 13,3 mg/24 u, patch for transdermal use

PortugalRivastigmina Teva

Rivastigmina Teva

Rivastigmina Teva

SloveniaRivastigmin Teva 4,6 mg/24 h transdermalni obliž

Rivastigmin Teva 9,5 mg/24 h transdermalni obliž

Rivastigmin Teva 13,3 mg/24 h transdermalni obliž

United KingdomErastig13.3 mg/24 h transdermal patch

Last revision date of this leaflet: March 2025

Detailed information on this medicinal product is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/